PLoS Biol:重磅!抗生素耐药性产生新方式

2016-12-31 佚名 生物谷

在一项新的研究中,来自荷兰格罗宁根大学和美国加州大学圣地亚哥分校的研究人员发现对抗生素敏感的细菌当它们的周围有足够多的耐药性细胞表达一种抗生素灭活因子时,也能够存活下来。相关研究结果于2016年12月27日发表在PLoS Biology期刊上,论文标题为“Collective Resistance in Microbial Communities by Intracellular Antibiot


在一项新的研究中,来自荷兰格罗宁根大学和美国加州大学圣地亚哥分校的研究人员发现对抗生素敏感的细菌当它们的周围有足够多的耐药性细胞表达一种抗生素灭活因子时,也能够存活下来。相关研究结果于2016年12月27日发表在PLoS Biology期刊上,论文标题为“Collective Resistance in Microbial Communities by Intracellular Antibiotic Deactivation”。

研究人员观察到已被绿色荧光蛋白(GFP)标记的葡萄球菌表达一种氯霉素耐药性基因。在它们附近的是黑色的没有携带这种耐药性基因的肺炎链球菌。在一种含有氯霉素的培养基中,发出绿色荧光的葡萄球菌开始生长和发生分裂,然而非耐药性的黑色的肺炎链球菌则不会。在一段时间后,单个黑色的肺炎链球菌开始发生分裂,而且它们甚至在生长上超过发出绿色荧光的葡萄球菌。

论文第一作者、格罗宁根大学合成生物学中心微生物学家Robin Sorg解释道,“这些耐药性的细胞摄取氯霉素,而且让它失活。在某个时间点上,培养基中的氯霉素浓度下降到一种临界水平下,因而非耐药性的细胞开始生长。”类似的事情也在之前观察过。“对青霉素产生耐药性的细胞能够分泌降解这种抗生素的β-内酰胺酶。但是在我们的研究中,抗生素是在耐药性的细胞中被灭活的。”

延时摄影

这一发现是利用时差显微镜取得的,而且利用计算建模和一种小鼠肺炎模型加以证实。“在小鼠体内,我们观察到当这些小鼠同时感染上耐药性细菌时,敏感的肺炎链球菌在接受氯霉素治疗后能够存活下来。”再者,这些结果排除了耐药性基因转移的情形。

因此,当耐药性的细菌存在时,敏感的细菌能够存活更长的时间,而且最终甚至能够竞争得过它们。对抗生素耐药性扩散来说,这意味着什么?Sorg说,“它是复杂的。我们知道抗生素使用导致耐药性选择。然而,我们并没有充分地理解着这些过程和抗生素耐药性为何如此快速地产生。类似我们的研究的单细胞研究有助填充其中的一些细节。”

代谢

一件应当值得注意的事情是这项实验中,这些敏感的细胞停止生长,但是不会死亡。“很多抗生素诱导的杀死机制依赖于发生分裂的细胞,或者至少依赖于发生活跃代谢的细胞。”不杀死这些敏感的细胞可能不会让它们变得更加强大,但是当然会给它们从它们的环境中获取耐药性基因的时间。

当利用抗生素治疗病人时,这种知识能够有助于医生。“我们知道我们应当慎重地使用这些药物,但是我们可能需要比我们所认为的更加谨慎。”Sorg概述了一种个人化治疗方法:存在于病人体内的非致病性细菌应当接受耐药性基因检查。“这会增加[耐药性基因]转移到病原菌中的风险。”

为了阻止非致病性微生物产生耐药性,尽可能少地使用抗生素当然是比较重要的。可能有朝一日,当对负责抗生素耐药性扩散的机制的理解更加完整时,人们就可能找到一种阻止它的方法。

原始出处

Robin A. Sorg, Leo Lin, G. Sander van Doorn, Moritz Sorg, Joshua Olson, Victor Nizet, Jan-Willem Veening.Collective Resistance in Microbial Communities by Intracellular Antibiotic Deactivation.PLoS Biol.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
    2017-05-22 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
    2017-01-02 1e128d2fm65(暂无匿称)

    这个有很大意义

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
    2017-01-02 xxxx1054
  7. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1767062, encodeId=ea241e6706280, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Feb 26 22:29:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070199, encodeId=883a20e0199e4, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Sep 27 08:29:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917358, encodeId=ed14191e3586a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 22 14:29:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167500, encodeId=b70f16e500d3, content=这个有很大意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Mon Jan 02 16:10:52 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441631, encodeId=3c541441631d5, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548998, encodeId=a9a4154899869, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604448, encodeId=61521604448f1, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Jan 02 05:29:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167065, encodeId=8f6716e065b1, content=抗生素滥用已成为人类未来最大的威胁之一, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Sat Dec 31 15:27:54 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
    2016-12-31 ishtar

    抗生素滥用已成为人类未来最大的威胁之一

    0

相关资讯

中国科研人员发现“解码”抗生素残留新法

该“解码”新方法可以快速降解阿莫西林、氧氟沙星和头孢等抗生素残留。中科院合肥物质科学研究院20日消息:该院技术生物所科研人员发现“解码”抗生素残留新方法。据了解,该“解码”新方法可以快速降解阿莫西林、氧氟沙星和头孢等抗生素残留。这一“解码”方法由该院技术生物所吴正岩研究员课题组近日研究发现。科研人员在利用电子束辐照技术降解医疗废弃物中抗生素残留的研究中取得进展。该工作对于医疗废弃物无害化处理具有重

抗生素耐药性或在2017年迎来临界点

停止服用这些药物?图片来源:Stuart Freedman/Panos 一个巨大的威胁正笼罩在人们头顶。2017年,很多人可能会开始死于普通细菌感染。 随着抗生素耐药性的增加,淋病和尿路感染等疾病变得不可治愈,随着全球明年达到一个新的临界点,这一形势将更加严峻。 “我们即将走到这一步:全世界农场动物消耗的抗生素将超过人类。”英国爱丁堡大学的Mark Woolhouse说。 这意味着更多

喝酒脸红的人,需要慎用3类药 !

喝酒脸红的罪魁祸首,不是乙醇,而是乙醛。在体内,酒精首先经催化变成乙醛,然后在乙醛脱氢酶2的作用下进一步分解。如果这种酶的活性出了问题,乙醛无法被及时代谢,大量滞留在体内,可能舒张面部血管,引起脸红,严重时可能对心、脑、肝、肾等器官造成伤害。喝酒容易脸红的人在服药时应谨慎,尤其要慎用以下三类药: 1、硝酸甘油:紧急用药,可能无效众所周知,心绞痛发作如不及时治疗,可能引起急性心肌梗死,甚至因严重心律

图说:常用抗生素抗菌谱 !

下面列出了常用抗生素及对其敏感的病原体,供大家参考。这个表格比较宽,直接看不清,请大家点击图片放大查看。同时建议保存到手机中,以备不时之需。注:● 越多说明越敏感

科普视频:为什么要慎用抗生素

抗生素,使那些曾经可能致命的细菌类疾病变得很容易治愈,研究表明,抗生素的出现,使人类的平均寿命提高了10岁,但是为什么要慎用抗生素呢?让我们一起通过下面这个视频了解慎用甚至禁用某些抗生素的原因。

一张处方,一场悲剧 ,望同行警惕 !

用药不适宜,轻则增加了患者医疗费用,造成个人和社会的的经济损失;重则导致药原性疾病,使用药者增加痛苦,甚至使人致残和死亡。下面给大家分享一个发生在某医院的真实案例。一、临床案例患者,男,73岁。湿疹。既往健康。无药敏史。静脉滴注0.9%氯化钠注射液250ml加注射用头孢曲松钠2.0g。20分钟时病人出现发热、寒战,体温38.6℃。停药,肌肉注射复方氨林巴比妥注射液2ml、异丙嗪注射液25mg、地塞